Acute myocardial infarction and transient elevated anticardiolipin antibody in a young adult with possible familial hypercholesterolemia: a case report : Anticardiolipin antibody and myocardial infarction

BMC Cardiovasc Disord. 2019 Jun 27;19(1):156. doi: 10.1186/s12872-019-1135-y.

Abstract

Background: Familial hypercholesterolemia (FH) can lead to premature coronary heart disease. Anticardiolipin antibody may be a contributor for thrombosis. Here, we report an adult with possible FH suffered from premature myocardial infarction that may be triggered by transient increased anticardiolipin antibody.

Case presentation: A 29-year-old male had presented with a history of 2-h chest pain and numbness of left upper arm before 5 days. The electrocardiogram (ECG) had demonstrated inferior wall myocardial infarction (MI). Five days later he was admitted to our hospital and diagnosed as acute MI and possible FH (premature coronary heart disease, low density lipoprotein cholesterol of 5.90 mmol/L) with increased anticardiolipin antibody (up to 120 RU/ml). Other auto-antibodies including β2-glicoprotein antibodies IgM, IgA, IgG, lupus anticoagulant (LA), antinuclear antibodies, anti-myocardial antibody were normal. Coronary artery angiography (CAG) showed right coronary artery was total occlusion from the middle segment. Then he underwent percutaneous coronary intervention with a stent. Four days later, he was discharged with complete recovery. CAG showed intra-stent restenosis and anticardiolipin antibody level was normal and the patient had no any symptoms at 6-month follow-up.

Conclusions: Transient elevated anticardiolipin antibody may be a trigger or biomarker of cardiac thrombotic events in younger atherosclerotic patients.

Keywords: Anticardiolipin antibody; Familial hypercholesterolemia; Myocardial infarction; Thrombosis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Anticardiolipin / blood*
  • Anticoagulants / therapeutic use
  • Biomarkers / blood
  • Coronary Occlusion / blood
  • Coronary Occlusion / diagnostic imaging
  • Coronary Occlusion / etiology*
  • Coronary Occlusion / therapy
  • Coronary Thrombosis / blood
  • Coronary Thrombosis / diagnostic imaging
  • Coronary Thrombosis / etiology*
  • Coronary Thrombosis / therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / drug therapy
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / etiology*
  • Myocardial Infarction / therapy
  • Percutaneous Coronary Intervention / instrumentation
  • Platelet Aggregation Inhibitors / therapeutic use
  • Stents
  • Treatment Outcome
  • Up-Regulation

Substances

  • Antibodies, Anticardiolipin
  • Anticoagulants
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors